Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Other Accumulated Expenses (2020 - 2022)

Historic Other Accumulated Expenses for Rapid Micro Biosystems (RPID) over the last 3 years, with Q2 2022 value amounting to $200000.0.

  • Rapid Micro Biosystems' Other Accumulated Expenses fell 6309.96% to $200000.0 in Q2 2022 from the same period last year, while for Jun 2022 it was $200000.0, marking a year-over-year decrease of 6309.96%. This contributed to the annual value of $338000.0 for FY2021, which is 19911.5% up from last year.
  • As of Q2 2022, Rapid Micro Biosystems' Other Accumulated Expenses stood at $200000.0, which was down 6309.96% from $86000.0 recorded in Q1 2022.
  • In the past 5 years, Rapid Micro Biosystems' Other Accumulated Expenses registered a high of $694000.0 during Q3 2021, and its lowest value of $86000.0 during Q1 2022.
  • For the 3-year period, Rapid Micro Biosystems' Other Accumulated Expenses averaged around $328833.3, with its median value being $269000.0 (2021).
  • Per our database at Business Quant, Rapid Micro Biosystems' Other Accumulated Expenses soared by 19911.5% in 2021 and then crashed by 6309.96% in 2022.
  • Quarter analysis of 3 years shows Rapid Micro Biosystems' Other Accumulated Expenses stood at $113000.0 in 2020, then skyrocketed by 199.12% to $338000.0 in 2021, then plummeted by 40.83% to $200000.0 in 2022.
  • Its last three reported values are $200000.0 in Q2 2022, $86000.0 for Q1 2022, and $338000.0 during Q4 2021.